CPA
TYRA icon

Capital Performance Advisors’s Tyra Biosciences TYRA Stock Holding History

Capital Performance Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$118 – 2520
2024
Q3 		$118 Buy
+5
New +$105 ﹤0.01% 2665

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Performance Advisors's TYRA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Tyra Biosciences (TYRA) in Q4 2024, closing a stake of 5 shares — an estimated $118 sold.

Capital Performance Advisors first reported a position in TYRA in Q3 2024 and held it in 1 quarter. The position peaked at $118 in Q3 2024. 113 funds tracked by Wall St. Rank hold TYRA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Tyra Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 5 Tyra Biosciences shares in Q4 2024, an estimated $118.
  • Capital Performance Advisors first reported a position in Tyra Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Tyra Biosciences position peaked at $118 in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Tyra Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.